Tryptophan: A gut microbiota-derived metabolites regulating inflammation

Area of Science:

• Immunology
• Gastroenterology
• Microbiology

Background:

• Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic intestinal disorders with increasing global prevalence.
• The exact causes of IBD are unknown but involve genetic factors, environmental influences, and a disrupted balance between gut microbiota and the immune system.
• Genome-wide association studies have identified IBD susceptibility genes, such as CARD9, which plays a role in innate immune responses and IL-22 signaling.

Purpose of the Study:

• To investigate the interaction between the CARD9 gene and gut microbiota in the production of microbiota-derived metabolites.
• To explore the role of tryptophan, a metabolite influenced by this interaction, in modulating intestinal inflammation.

Main Methods:

• Analysis of the interaction between CARD9 and gut microbiota.
• Investigating the generation of microbiota-derived tryptophan metabolites.
• Assessing the impact of tryptophan on intestinal inflammation in susceptible hosts.

Main Results:

• The study highlights a significant interaction between CARD9 and gut microbiota in generating tryptophan metabolites.
• Tryptophan was identified as a key metabolite that helps to dampen intestinal inflammation.
• This interaction is crucial for maintaining gut homeostasis in individuals susceptible to IBD.

Conclusions:

• The CARD9 gene and gut microbiota play a critical role in the production of immunomodulatory metabolites like tryptophan.
• Tryptophan metabolism represents a potential therapeutic target for managing inflammatory bowel diseases.
• Understanding these complex interactions is vital for developing novel strategies to treat IBD.